Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

University of Pennsylvania, The Barbara Ann Karmanos Cancer Institute, Wayne State University, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, University of Virginia, University of Washington, Seattle Cancer Care Alliance, Cleveland Clinic, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, Fargo VA Health Care System, National Taiwan University Hospital, University of California, San Francisco, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), NYU Langone Health